Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Niclosamide - First Wave BioPharma

Drug Profile

Niclosamide - First Wave BioPharma

Alternative Names: FW 424; FW-1022; FW-420; FW-CD; FW-COV; FW-ICI-AC; FW-UC; FW-UP; micronized niclosamide - First Wave Biopharma

Latest Information Update: 01 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator First Wave Bio
  • Developer First Wave Bio; First Wave BioPharma
  • Class Anthelmintics; Anti-inflammatories; Antibacterials; Antineoplastics; Antivirals; Benzamides; Chlorophenols; Nitrobenzenes; Skin disorder therapies; Small molecules
  • Mechanism of Action Autophagy stimulants; Mitochondrial oxidative phosphorylation uncouplers; MTOR protein inhibitors; NF-kappa B inhibitors; Notch signalling pathway inhibitors; STAT3 transcription factor inhibitors; Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ulcerative proctitis; Ulcerative proctosigmoiditis
  • Preclinical Crohn's disease; Gastroenteritis; Ulcerative colitis
  • Discontinued Gastrointestinal disorders

Most Recent Events

  • 27 Dec 2023 Undisclosed company enters into non-binding term sheet agreement to acquire Niclosamide from First Wave Biopharma
  • 25 Apr 2023 First Wave BioPharma has patents pending for compositions and methods for treating conditions characterized by an abnormal inflammatory response in the US prior to April 2023
  • 04 Oct 2022 First Wave Bio terminates phase I/II trials in Ulcerative proctitis and Ulcerative proctosigmoiditis in Italy (Rectal) due to Covid-19 (NCT03521232)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top